Kenvue Inc. $KVUE Holdings Increased by Independent Franchise Partners LLP

Independent Franchise Partners LLP grew its holdings in Kenvue Inc. (NYSE:KVUE) by 56.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 48,146,476 shares of the company’s stock after purchasing an additional 17,343,785 shares during the period. Kenvue comprises approximately 5.3% of Independent Franchise Partners LLP’s holdings, making the stock its 4th largest holding. Independent Franchise Partners LLP owned approximately 2.51% of Kenvue worth $830,527,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Physician Wealth Advisors Inc. increased its stake in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares during the period. Elyxium Wealth LLC purchased a new stake in Kenvue in the fourth quarter worth $26,000. SBI Securities Co. Ltd. increased its stake in Kenvue by 82.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after purchasing an additional 1,027 shares during the period. Leonteq Securities AG purchased a new stake in Kenvue in the fourth quarter worth $45,000. Finally, DV Equities LLC purchased a new stake in Kenvue in the fourth quarter worth $46,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of KVUE stock opened at $18.03 on Thursday. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $22.87. The stock’s 50-day moving average is $17.49 and its 200 day moving average is $17.56. The company has a market cap of $34.61 billion, a P/E ratio of 21.21, a PEG ratio of 1.40 and a beta of 0.54. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. During the same quarter last year, the company earned $0.24 earnings per share. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. Research analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were paid a $0.2075 dividend. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.6%. Kenvue’s dividend payout ratio (DPR) is 97.65%.

Insider Buying and Selling

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.59% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on KVUE shares. Barclays dropped their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 14th. Canaccord Genuity Group increased their price target on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research report on Wednesday, February 18th. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday. UBS Group dropped their price target on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 7th. Finally, Argus raised Kenvue to a “hold” rating in a research report on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.